Dose-confirmatory Bridging Study in Total Hip Replacement

Model scores of the 29,894 trials active now.

Model score 9% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (493 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: hourscontrastleftbleedingreplacement
  Phrases that lowered it: japaneseinvestigatoronce dailyinvestigate theto investigate
• Minimum age: 20 (lowers risk) · Who can join
• Blinding: triple (raises risk) · Design
• Sponsor's past termination rate: 5.1% (lowers risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Number of arms: 4 (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Trials the sponsor started in the prior 2 years: 127 (lowers risk) · Sponsor's track record
• Sponsor's past trials: 335 (lowers risk) · Sponsor's track record
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Disease area, neurology: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 19.7% (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Dose-confirmatory Bridging Study in Total Knee Replacement NCT01206972 · started 2010 · scored riskier than 10% of active trials completed
• Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty NCT01720108 · started 2013 · scored riskier than 48% of active trials completed
• Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery NCT01344954 · started 2011 · scored riskier than 32% of active trials completed
• Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery NCT00793234 · started 2008 · scored riskier than 23% of active trials completed
• Blood-sparing During Hip Prosthesis Surgery With Exacyl® in Patients Treated With Rivaroxaban NCT02403596 · started 2015 · scored riskier than 60% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.